The rise in the importance of out-sourcing has been one of the most dramatic changes in the drug discovery landscape over the past 20 years.

Discovery Analytical Consulting (DAC) has established a consortium of companies to address the need for flexible drug discovery services. Via our network of providers, we have access to a range of services including:

  • Synthetic chemistry
  • Purification including chiral resolution
  • in vitro pharmacology and ADME
  • Metabolite ID
  • PK and bioanalysis (including large molecule)
  • in vivo efficacy studies
  • Immunology
  • Imaging

This is supported by experienced study management and consultancy including expert DMPK interpretation.

Core Values

  • Highly responsive to client needs
  • A consistent, single point of contact provides the ongoing continuity that is crucial to providing efficient support
  • Regular and open communication is provided at all times to ensure a successful collaboration
  • Data formatted according to your reporting needs

We can provide external study management including:

  • Selection of appropriate partners
  • Assistance with administration (quotes, PWOs etc)
  • Liaison with CROs to ensure delivery within agreed timelines compatible with screening cycles
  • Scrutiny of raw and processed data and calculations for Quality and Accuracy including calibration and batch control data
  • Audit of final reports for accuracy
  • Advise on acceptability/reliability of data and any need for repeats

DAC is working with ChemPharmaServe to act as an outsourcing gateway to a diverse range of research, development and manufacturing services including the provision of materials you need to facilitate your research and development plans. ChemPharmaServe take care of production of the compounds you need and hence free your time to focus on other discovery and development challenges. They help to develop, make or source the key compounds and active drugs you need in order to progress your lead discoveries to proof of concept and beyond.

In short, they address your synthetic chemistry, route development, manufacturing and regulatory needs by:

  • Finding hard-to-find commercial fine chemicals and active drugs
  • Synthesising non-commercial chemicals
  • Helping with developing and producing drug candidates to cGMP
  • Manufacturing fine chemicals
  • Identifying enabling technologies that facilitate drug development
  • Filling the resource and skills gap by providing project management

In addition, ChemPharmaServe are offering training courses for prospective consultants. This is a new offering that is relevant to all experienced scientists and managers who are considering a career change and provides step-by-step training on starting and working as an independent consultant. Highly recommended!

Further Information

For further information regarding these services and how we can help to support your R&D programmes, please contact me below.

key logo.jpg

Key Organics Limited

Key Organics has over 30 years’ proven expertise and competence, supplying to a global client base their high quality ‘BIONET'-branded catalogue products (>100,000) for early-stage drug discovery research.

Product lines include; Fragments, Biochemicals, Screening Compounds, Research Intermediates, AgrimediatesTM and Core Scaffolds.

They also have extensive experience in the delivery of bespoke Chemistry Services, e.g. Custom & Contract Synthesis and Collaborative R&D. They have an enviable reputation in FTE services provision from their highly-qualified and skilled team of chemists.


Operating out of their own premises in Cornwall, they cater primarily for the pharmaceutical, biotechnology and agro/petrochemical industries.

Further Information

For further information regarding these services and how we can help to support your research programmes, please contact me below.

We work closely with Bio-Mimetic Chromatography Ltd (BMC) which is owned and run by Professor Klara Valko to support compound optimisation and promote the use of HPLC for biomimetic property measurements.

Bio-mimetic chromatography involves the use of human proteins and phospholipid to model the in vivo distribution of compounds. In addition to making these measurements, BMCC provides a comprehensive package of predictions including in vivo distribution, drug efficiency and early dose estimation. This information leads to fewer costly animal tests on compounds likely to fail due to poor efficacy or toxicity. More information on drug efficiency can help with early dose estimation.

BMC's services include:

  • Measurement of compound physchem properties, in vivo distribution prediction via measurement of compound affinity for IAM, HSA and AGP; to provide drug efficiency and dose prediction
  • Lead Optimisation support to help you select and improve the best candidates to achieve your aims.
  • Training Courses on HPLC, lipophilicity, bio-mimetic chromatography and other applications of chromatography for successful drug discovery

Further Information

For further information regarding these services and how we can help to support your research programmes, please contact me below.

CEMAS Ltd Bioanalytical support

Discovery Analytical Consulting (DAC) and CEM Analytical Services (CEMAS) work together to provide bioanalysis solutions in the drug discovery arena. This can either be stand-alone bioanalytical support or integrated with a broad range of pharmacokinetic and in vivo efficacy services available through our preferred supplier Saretius Limited.

CEMAS is a long established and dynamic contract analytical company providing method development and bioanalysis from discovery through to phase III clinical trials to companies requiring affordable and flexible support. DAC offers a range of consulting services for discovery analytical chemistry, compound management and external study management.  Both CEMAS and DAC are based in south east England, close to major transport networks, and we fully understand the needs of companies of all sizes, the issues confronting them and the importance of ongoing communication.
All CEMAS activities are backed by comprehensive in-house method development, validation and transfer know-how. The company has the capacity to carry out large-scale sample analysis with full accreditation to GLP, GMP and GCP, where required. Sample and equipment details are as follows:

  • Animal and Human biological fluids and tissues analysed in all formats

  • Automated High Throughput systems

  • 9x AB Sciex LC-MS/MS including 4x API 5500

  • 2x Spark Holland Pharma automated SPE systems

  • 3x Agilent 6890/5973 GC-MS

  • 1x Agilent 7800 ICP-MS

  • Data formatted to meet customer reporting needs

CEMAS has highly skilled scientists using excellent equipment and the commitment to invest more when necessary. This high quality leads on to greater reliability and a reduction in costs for large volumes.

Further Information

Please contact me below for further information regarding our capabilities, capacities, procedures and pricing, or to discuss how we can further assist in your out-sourcing of bioanalysis and other studies.


Abundnz B.V.

Abundnz offers advanced analytical solutions for biotechnology, pharmaceutical and diagnostic companies as well as supporting life sciences research. They specialize in the bioanalysis of innovative medicines such as peptide and protein drugs, oligonucleotides and nanomedicines using LC-MS. Their expertise includes the measurement of analytes at extremely low concentrations in complex matrices with small sample volumes using high end separation and detection technologies. Abundnz has developed a unique ultrasensitive assay (pAMS) for bioanalytical studies with large molecule drugs.

Abundnz's services include:

  • Bioanalysis of complex drug molecules - LC-MS, ELISA, pAMS
  • Intracellular drug localization and quantitation
  • Biomarker discovery and validation
  • Biomarker analysis
  • Epitope mapping
  • Proteomics
  • Monitoring of complex diseases
  • Clinical Bioassay development

They also offer biological assays, immunoassays, imaging MS, histopathology, cell separations and in vitro systems for preclinical drug research through associate company Immundnz, a UK-based CRO with a laboratory capacity for cell cultures and various cellular assays offering solutions that require ‘immune modelling’ and laboratory based in vitro experimental testing of drugs. 

Tissue damage study is the prime focus of Immundnz as it is the central driver of an immune response whether the damage is an outcome of a drug molecule or a pathogen or endogenous metabolites. Understanding this feature of a drug through proper immune modelling is of great importance in predicting its immunogenicity and secondary pathogenesis. Immundnz emphasise on the immune modelling of a candidate therapeutic to understand the immune response as a whole to the candidate biomolecule.
As experienced immunologists, Immundnz will help you design and test a model to analyse the immunology of your product.

Further Information

For further information regarding these services and how we can help to support your research programmes, please contact me below.

EM Analytical_Logo Final Chosen.png

EM Analytical: Advanced Microscopy Services

Modern imaging technologies are extremely powerful and versatile with applications in drug discovery, toxicology and many other fields of research. Where other techniques only provide an average value for a given sample, the spatial information from high resolution imaging gives key insights into the distribution of molecules, e.g. in cells and tissues. A picture truly is worth a thousand words...

Based at Alderley Park, the UK’s largest bioscience campus just a few miles from Manchester Airport, EM Analytical combines expertise from a broad array of scientific and technical fields to provide state-of-the-art imaging services.  Their services include electron microscopy, fluorescence microscopy and chemical analysis.

They have an inverted fluorescence microscope, perfect for monitoring drug diffusion rates, observing distribution and penetration into tissue. This can support PK/PD, in vitro viability studies, toxicology screening and histopathology. Many therapeutic agents may be tagged with fluorophores, allowing them to be selectively imaged within a sample using fluorescence microscopy. In this way, their position may be tracked as a function of time, dose, etc. Different structures may be tagged with different fluorophores, eg. nucleus or cytoskeleton, allowing you to track the progress of the drug as it (hopefully) reaches its target.

Their electron microscopes are particularly useful for observing the internal structures of cells, viruses and bacteria. Transmission electron microscopy provides single-nanometer resolution. Their scanning electron microscopes are fitted with a range of detectors, including X-ray elemental analysis. This can give quantitative chemical information for nano-scale features, such as contamination or nanoparticles, as well as visualising the distribution of elements within the sample. Alternatively, transmission electron microscopy can directly image the interior structure of cells, allowing you to monitor uptake of things like nanoparticles and check where they accumulate within the cell. Transmission electron microscopy is also an industry-standard technique for characterising the nanoparticles themselves, directly providing information such as shape, average size and size distribution with minimal sample volumes required.

Their facility is even available on an open access basis for you to use directly. Experienced users and novice researchers are equally welcome and all necessary support and training will be provided.

Further Information

Please contact me below for a brochure describing the full range of equipment available, sample preparation techniques and service overview.

MIP Diagnostics Limited

Discovery Analytical Consulting works in partnership with MIP Diagnostics Ltd to promote and support their revolutionary technology in the field of Molecularly Imprinted Polymers (MIPs).

MIPs are Affinity Reagents (sometimes referred to as plastic antibodies) whose potential applications include:

  • Extraction devices for chemical analysis
  • Purification
  • Research tools for analysis of molecular disposition and interactions
  • Sensors and assays, including tests of precision medicine and accompanying diagnostics
  • Imaging
  • Drug Delivery
  • Antidotes

MIP Diagnostics' proprietary technology affords a high degree of control over the polymerisation process and hence over the size of nanoparticle produced (30-300nm) with high uniformity of the binding site. Self-assembly of monomers around the target ensures high affinity and selectivity similar to antibodies but with major advantages in terms of their stability and robustness. MIPs withstand organic solvents and extremes of pH and temperature and hence can be used in applications that no antibody would survive.

With around 5000 monomers to choose from (compared to 20 amino acids) and using a mixture of computational and combinatorial techniques and in-house knowhow, MIPs can be prepared for almost any target ranging from very small molecules to viruses. No immune response is required and no animals are used. Initial development typically takes between 2 and 6 weeks with subsequent batches prepared in a matter of hours with very high reproducibility both in terms of their size and affinity. Functionalised particles (fluorescent, magnetic and others) are readily prepared.

Further Information

Contact me below for further literature or to arrange a discussion about your application.

Quote promotion code DAC10 to receive an introductory discount of 10% on your first order.